These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 3698462)

  • 21. Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite.
    Sum CY; Yacobi A; Kartzinel R; Stampfli H; Davis CS; Lai CM
    Clin Pharmacol Ther; 1983 Oct; 34(4):427-34. PubMed ID: 6617063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of ICI 141,292 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man.
    Pringle TH; O'Connor PC; McNeill AJ; Finch MB; Riddell JG; Shanks RG
    Br J Clin Pharmacol; 1986 Mar; 21(3):249-58. PubMed ID: 2870732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular beta-adrenergic blocking effects of bornaprolol in humans: relation to dose and plasma concentration.
    Cheymol G; Jaillon P; Lecoq B; Lecoq V; Cheymol A; Krumenacker M
    J Cardiovasc Pharmacol; 1987 Jun; 9(6):694-8. PubMed ID: 2442536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The assessment in man of the beta-adrenoceptor blocking activity and cardioselectivity of H-I 42 BS, a long acting beta-adrenoceptor blocking drug.
    Pringle TH; Deering AH; Scott MG; Harron DW; Shanks RG
    Br J Clin Pharmacol; 1987 Apr; 23(4):411-23. PubMed ID: 2883988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacodynamics and onset of action of esmolol in anesthetized dogs.
    Quon CY; Gorczynski RJ
    J Pharmacol Exp Ther; 1986 Jun; 237(3):912-8. PubMed ID: 2872328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Esmolol and beta-adrenergic blockade.
    Wolman RL; Fiedler MA
    AANA J; 1991 Dec; 59(6):541-8. PubMed ID: 1686346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiarrhythmic activity of esmolol (ASL-8052)--a novel ultra-short acting beta-adrenoreceptor blocking agent.
    Klein G; Wirtzfeld A; Alt E; Steck J; Saunders R; Hulse J; Kartzinel R; Lee R; Laddu AR
    Int J Clin Pharmacol Ther Toxicol; 1984 Feb; 22(2):112-7. PubMed ID: 6142005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effects in humans of a new beta adrenergic receptor blocking agent on tachycardia induced with isoprenaline].
    Fuccella LM; Bianchi-Porro G; Foresti A; Mandelli V
    Minerva Cardioangiol; 1973 Dec; 21(12):854-9. PubMed ID: 4149917
    [No Abstract]   [Full Text] [Related]  

  • 29. Plasma levels and effects of metoprolol on blood pressure, adrenergic beta receptor blockade, and plasma renin activity in essential hypertension.
    von Bahr C; Collste P; Frisk-Holmberg M; Haglund K; Jorfelt L; Orme M; Ostman J; Sjoqvist F
    Clin Pharmacol Ther; 1976 Aug; 20(2):130-7. PubMed ID: 7373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. beta-2 Adrenergic blockade evaluated with epinephrine after placebo, atenolol, and nadolol.
    Hiatt WR; Wolfel EE; Stoll S; Nies AS; Zerbe GO; Brammell HL; Horwitz LD
    Clin Pharmacol Ther; 1985 Jan; 37(1):2-6. PubMed ID: 2856902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pafenolol, a new beta 1-selective blocking agent, in mild hypertension. Result of an inpatient study and a subsequent outpatient follow-up.
    Sigurdsson JA; Bengtsson C; Bjurö T
    Eur J Clin Pharmacol; 1984; 26(5):549-53. PubMed ID: 6147255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human pharmacokinetic and pharmacodynamic studies on the atenolo (ICI 66,082), a new cardioselective beta-adrenoceptor blocking drug.
    Conway FJ; Fitzgerald JD; McAinsh J; Rowlands DJ; Simpson WT
    Br J Clin Pharmacol; 1976 Apr; 3(2):267-72. PubMed ID: 973955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic, electrocardiographic, and hemodynamic responses to increased circulating adrenaline: effects of selective and nonselective beta adrenoceptor blockade.
    Hansen O; Johansson BW; Nilsson-Ehle P
    Angiology; 1990 Mar; 41(3):175-88. PubMed ID: 1968731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Esmolol hydrochloride: an ultrashort-acting, beta-adrenergic blocking agent.
    Angaran DM; Schultz NJ; Tschida VH
    Clin Pharm; 1986 Apr; 5(4):288-303. PubMed ID: 2871961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interactions of esmolol and adenosine in atrioventricular nodal-dependent supraventricular tachycardia: implication for the cellular mechanisms of adenosine.
    Chang KC; Lin YC; Chen JY; Chou HT; Hung JS
    Cardiology; 2002; 97(3):138-46. PubMed ID: 12077566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of beta-adrenoceptors mediating renin release produced by isoproterenol in conscious dogs.
    Himori N; Izumi A; Ishimori T
    Am J Physiol; 1980 May; 238(5):F387-93. PubMed ID: 6103674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of betaxolol, propranolol, and atenolol on isoproterenol-induced beta-adrenoceptor responses.
    Riddell JG; Shanks RG
    Clin Pharmacol Ther; 1985 Nov; 38(5):554-9. PubMed ID: 2865028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peripheral vascular effects of beta-adrenoceptor blockade: comparison of two agents.
    Cooke ED; Maltz MB; Smith RE; Bowcock SA; Watkins CJ; Camm AJ
    Br J Clin Pharmacol; 1987 Sep; 24(3):359-66. PubMed ID: 2889459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Test doses: optimal epinephrine content with and without acute beta-adrenergic blockade.
    Guinard JP; Mulroy MF; Carpenter RL; Knopes KD
    Anesthesiology; 1990 Sep; 73(3):386-92. PubMed ID: 1975483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduction of beta-adrenergic receptors by tertatolol: an additional mechanism for beta-adrenergic blockade.
    De Blasi A; Lipartiti M; Pirone F; Rochat C; Prost JF; Garattini S
    Clin Pharmacol Ther; 1986 Mar; 39(3):245-54. PubMed ID: 2868822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.